FDA Fast Track Designation to Debio 1347, for Unresectable or Metastatic Tumors with Specific FGFR Gene Alterations.
Debiopharma just analysis ST has granted fast track designation compound, DEbio 1347. It is a small molecule inhibitor of fibroblast growth factor receptor 1, 2 and 3. This was the treatment of patients with unresectable and metastatic tumors with a specific FGFR gene alteration. From the phase I clinical study, an investigational drug application was filed. FGFR mutations have been implicated in a variety of tumors. This is an exciting time for this family of inhibitors as well as the clinical development of FGFR as a target.
News From PSMG
The latest news at Pacific Shores Medical Group
Disclaimer: This site is not designed to and does not provide medical advice, professional diagnosis, opinion, treatment or services to you or to any other individual. Through this site and linkages to other sites, Pacific Shores Medical Group provides general information for educational purposes only. The information provided in this site, or through linkages to other sites, is not a substitute for medical or professional care, and you should not use the information in place of a visit, call consultation or the advice of your physician or other healthcare provider. Pacific Shores Medical Group is not liable or responsible for any advice, course of treatment, diagnosis or any other information, services or product you obtain through this site.